[go: up one dir, main page]

MX2013003077A - BREAST CANCER DIAGNOSIS. - Google Patents

BREAST CANCER DIAGNOSIS.

Info

Publication number
MX2013003077A
MX2013003077A MX2013003077A MX2013003077A MX2013003077A MX 2013003077 A MX2013003077 A MX 2013003077A MX 2013003077 A MX2013003077 A MX 2013003077A MX 2013003077 A MX2013003077 A MX 2013003077A MX 2013003077 A MX2013003077 A MX 2013003077A
Authority
MX
Mexico
Prior art keywords
cancer
breast cancer
cancer diagnosis
patient
determining
Prior art date
Application number
MX2013003077A
Other languages
Spanish (es)
Inventor
Josef Penninger
Daniel Schramek
Georg Schett
Martin Widschwendter
Ian J Jacobs
Usha Menon
Original Assignee
Imba Inst Molekulare Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imba Inst Molekulare Biotech filed Critical Imba Inst Molekulare Biotech
Publication of MX2013003077A publication Critical patent/MX2013003077A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/57515—
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a métodos y medios para detectar cáncer o para predecir a un paciente en desarrollo de cáncer o para determinar la velocidad de progresión del cáncer en un paciente que sufre del cáncer, el cual comprende determinar la actividad de RANKL y/o la cantidad de OPG en una muestra del paciente.The present invention relates to methods and means for detecting cancer or for predicting a cancer developing patient or for determining the rate of cancer progression in a patient suffering from cancer, which comprises determining the activity of RANKL and / or the amount of OPG in a patient sample.

MX2013003077A 2010-09-22 2011-09-22 BREAST CANCER DIAGNOSIS. MX2013003077A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10178345A EP2434285A1 (en) 2010-09-22 2010-09-22 Breast cancer diagnostics
PCT/EP2011/066514 WO2012038505A1 (en) 2010-09-22 2011-09-22 Breast cancer diagnostics

Publications (1)

Publication Number Publication Date
MX2013003077A true MX2013003077A (en) 2013-07-29

Family

ID=43302989

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003077A MX2013003077A (en) 2010-09-22 2011-09-22 BREAST CANCER DIAGNOSIS.

Country Status (16)

Country Link
US (2) US20130316374A1 (en)
EP (2) EP2434285A1 (en)
JP (1) JP6006216B2 (en)
KR (1) KR20130101062A (en)
CN (1) CN103238067B (en)
AU (1) AU2011306918B2 (en)
BR (1) BR112013006683A2 (en)
CA (1) CA2811558A1 (en)
DK (1) DK2619582T3 (en)
ES (1) ES2533762T3 (en)
IL (1) IL225441A0 (en)
MX (1) MX2013003077A (en)
NZ (1) NZ608208A (en)
PH (1) PH12013500544A1 (en)
RU (1) RU2013118332A (en)
WO (1) WO2012038505A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
WO2014066860A2 (en) * 2012-10-25 2014-05-01 Cedars-Sinai Medical Center Methods of prognosticating and treating cancer
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN110289092A (en) 2013-03-14 2019-09-27 奥特拉西斯公司 The method for improving medical diagnosis on disease using surveyed analyte
JP6465033B2 (en) * 2013-12-24 2019-02-06 ソニー株式会社 Inspection server, communication terminal, inspection system, and inspection method
MX2016014281A (en) 2014-05-22 2017-02-22 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP6952056B2 (en) 2016-01-22 2021-10-20 オートレイシーズ, インク.Otraces, Inc. Systems and methods to improve disease diagnosis
MX2018011705A (en) 2016-04-01 2019-06-10 Therapeuticsmd Inc Steroid hormone pharmaceutical composition.
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3147270A1 (en) * 2019-07-13 2021-01-21 Otraces Inc. Improving diagnosis for various diseases using tumor microenvironment active proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE122010000048I1 (en) 1996-12-23 2011-05-05 Immunex Corp LIGAND FOR RECEPTOR ACTIVATOR OF NF-KAPPA B, LIGAND IS A MEMBER OF THE TNF SUPERFAMILY
CA2781623A1 (en) 1997-04-15 1998-10-22 Daiichi Sankyo Company, Limited Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EP1717315A3 (en) 1997-04-16 2007-06-20 Amgen Inc. Osteoprotegerin binding proteins and receptors
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US20040002067A1 (en) * 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
WO2005060627A2 (en) * 2003-12-10 2005-07-07 Auxeris Therapeutics, Inc. Methods of assessing the risk of non-traumatic bone fracture
US20080107597A1 (en) 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
WO2007132512A1 (en) * 2006-05-12 2007-11-22 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
CN101514232B (en) * 2009-03-25 2013-06-19 上海科新生物技术股份有限公司 RANKL-Fc fusion protein, preparation method and application thereof
CN101571545A (en) * 2009-06-09 2009-11-04 广州益善生物技术有限公司 Liquichip for parallelly detecting multiterm markers of cancer bone metastasis and preparation method thereof

Also Published As

Publication number Publication date
EP2434285A1 (en) 2012-03-28
WO2012038505A1 (en) 2012-03-29
US20170102388A1 (en) 2017-04-13
NZ608208A (en) 2014-07-25
AU2011306918A1 (en) 2013-04-04
CA2811558A1 (en) 2012-03-29
CN103238067B (en) 2014-12-17
EP2619582B1 (en) 2015-01-07
CN103238067A (en) 2013-08-07
AU2011306918B2 (en) 2014-08-07
JP6006216B2 (en) 2016-10-12
US20130316374A1 (en) 2013-11-28
EP2619582A1 (en) 2013-07-31
KR20130101062A (en) 2013-09-12
RU2013118332A (en) 2014-10-27
JP2013542419A (en) 2013-11-21
DK2619582T3 (en) 2015-01-19
IL225441A0 (en) 2013-06-27
BR112013006683A2 (en) 2016-06-07
PH12013500544A1 (en) 2017-08-23
ES2533762T3 (en) 2015-04-14

Similar Documents

Publication Publication Date Title
MX2013003077A (en) BREAST CANCER DIAGNOSIS.
BR112014031365A2 (en) methods of detecting disease or conditions
EA201390149A1 (en) METHODS FOR DETECTING DISEASES OR PATHOLOGICAL CONDITIONS USING PHAGOCYTARY CELLS
MX382244B (en) Methods for detecting signatures of disease or conditions in bodily fluids
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
MX355416B (en) Lung cancer biomarkers and uses thereof.
BR112013010952A2 (en) NMR systems and methods for rapid detection of analytes
WO2011095623A3 (en) miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
WO2014028884A3 (en) Cancer diagnostics using biomarkers
MX357402B (en) Method of predicting breast cancer prognosis.
EA201390762A1 (en) NEW BIOMARKERS TO PREDICT THE OUTCOME OF ANTICATIVE IMMUNOTHERAPY
EA201400117A1 (en) METHODS AND NUCLEIC ACIDS FOR DETERMINATION OF THE PREDICTION IN CANCER PATIENTS
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
NZ629555A (en) Monocyte biomarkers for cancer detection
WO2012109632A3 (en) Crown-like structures as a biomarker for cancer risk and cancer prognosis
MX358474B (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases.
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
NZ729773A (en) Biomarkers for disease progression in melanoma
MX351228B (en) Diagnostic and treatment methods using a ligand library.
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
EP2686437A4 (en) MUCINE 5B, A SPECIFIC BIOMARKER FOR PANCREATIC LIQUID CYSTS, USEFUL IN ESTABLISHING A PRECISE DIAGNOSIS OF MUCINIC KYSTOS, AND OTHER MARKERS FOR THE DETECTION OF PANCREATIC CANCER
MA40636A (en) METHODS TO DETECT PROSTATE CANCER
ES2361808B8 (en) METHOD OF OBTAINING USEFUL DATA FOR THE DIAGNOSIS OR FORECAST OF COLORRECTAL CANCER.
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies

Legal Events

Date Code Title Description
FA Abandonment or withdrawal